# Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

> **NCT05683990** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Diamyd Medical AB** · enrollment: 5 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Autoimmune Diseases
- Prevention

## Interventions

- **DRUG:** Diamyd

## Key facts

- **NCT ID:** NCT05683990
- **Lead sponsor:** Diamyd Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05683990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05683990, "Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05683990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*